VanEck Vectors Biotech ETF (BBH)
|Ex-Dividend Date||Dec 20, 2021|
|Day's Range||146.31 - 149.67|
|Inception Date||Dec 20, 2011|
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Top 10 Holdings64.33% of assets
|Dec 20, 2021||$0.3972||Dec 27, 2021|
|Dec 21, 2020||$0.6079||Dec 28, 2020|
|Dec 23, 2019||$0.4724||Dec 30, 2019|
|Dec 20, 2018||$0.551||Dec 27, 2018|
|Dec 18, 2017||$0.683||Dec 22, 2017|
|Dec 19, 2016||$0.327||Dec 23, 2016|
Biotechnology stocks and exchange traded funds are into a second year of disappointing investors, but that condition won't be permanent. With that in mind, investors evaluating ideas for a biotech resur...
Sector ETF report for BBH
Biotechnology sector-related exchange traded funds gained on Monday, with Moderna Inc. (NasdaqGS: MRN) sitting among the top performers in the S&P 500, on renewed COVID-19 concerns as China implements l...
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.
NEW YORK--(BUSINESS WIRE)--VanEck announced today the following 2021 annual distributions per share for its VanEck® equity exchange-traded funds
Biotechnology equities are lagging the healthcare sector and the broader market this year, but with new variants of the coronavirus expected to continue popping up in 2022, it's impossible to ignore bio...
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.